Precision Therapeutics Inc. (AIPT) Forms $0.89 Double Bottom; Profile of 2 Analysts Covering John Laing Infrastructure Fund Ltd. (LON:JLIF)

Among 4 analysts covering John Laing Infrastructure Fund Ltd (LON:JLIF), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. John Laing Infrastructure Fund Ltd had 7 analyst reports since December 7, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of JLIF in report on Thursday, March 17 with “Sector Performer” rating. Macquarie Research maintained it with “Neutral” rating and GBX 125 target in Wednesday, October 12 report. As per Thursday, February 22, the company rating was maintained by RBC Capital Markets. The stock has “Overweight” rating by JP Morgan on Tuesday, October 24. On Monday, December 7 the stock rating was downgraded by RBC Capital Markets to “Sector Performer”. The rating was maintained by Peel Hunt with “Neutral” on Friday, September 16. The rating was maintained by JP Morgan on Tuesday, November 14 with “Overweight”. See John Laing Infrastructure Fund Ltd. (LON:JLIF) latest ratings:

22/02/2018 Broker: RBC Capital Markets Rating: Sector Performer Old Target: GBX 135.00 New Target: GBX 120.00 Maintain
14/11/2017 Broker: JP Morgan Rating: Overweight Maintain
24/10/2017 Broker: JP Morgan Rating: Overweight Maintain

Precision Therapeutics Inc. (AIPT) formed double bottom with $0.83 target or 7.00% below today’s $0.89 share price. Precision Therapeutics Inc. (AIPT) has $10.49M valuation. The stock increased 0.45% or $0.004 during the last trading session, reaching $0.889. About 56,616 shares traded. Precision Therapeutics Inc. (NASDAQ:AIPT) has declined 45.89% since April 23, 2017 and is downtrending. It has underperformed by 57.44% the S&P500.

The stock decreased 0.18% or GBX 0.2 during the last trading session, reaching GBX 113.8. About 213,333 shares traded. John Laing Infrastructure Fund Ltd. (LON:JLIF) has 0.00% since April 23, 2017 and is . It has underperformed by 11.55% the S&P500.